RJA
SGTX

Raymond James & Associates’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Raymond James & Associates’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,723
Closed -$20.8K – 4027
2023
Q1 		$20.8K Buy
+1,723
New +$17.9K ﹤0.01% 3799

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's SGTX Position: Q2 2023 in Review

Raymond James & Associates sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 1,723 shares — an estimated $20.8K sold.

Raymond James & Associates first reported a position in SGTX in Q1 2023 and held it in 1 quarter. The position peaked at $20.8K in Q1 2023. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

  • Raymond James & Associates reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 1,723 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $20.8K.
  • Raymond James & Associates first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Raymond James & Associates's Sigilon Therapeutics, Inc. Common Stock position peaked at $20.8K in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.